Formulation Evaluation Sustained Release by Venkata Raghava (6 results)
- Softcover
Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
Contact seller5-star sellerCondition: New
£ 82.92
£ 10.00 shippingShips from United Kingdom to U.S.A.Quantity: 1 available
Paperback. Condition: Brand New. 104 pages. 8.66x5.91x0.24 inches. In Stock.
- Softcover
Seller: preigu, Osnabrück, Germanypreigu
Contact seller5-star sellerCondition: New
£ 39.03
£ 60.15 shippingShips from Germany to U.S.A.Quantity: 5 available
Taschenbuch. Condition: Neu. Formulation and Evaluation of Sustained release tablets of Tizanidine | Venkata Raghava Reddy P. (u. a.) | Taschenbuch | 104 S. | Englisch | 2017 | LAP LAMBERT Academic Publishing | EAN 9783330051560 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[…at]bod[dot]de | Anbieter: preigu.
Language: English
Published by LAP LAMBERT Academic Publishing Feb 2017, 2017
- Softcover
- Print on Demand
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, GermanyBuchWeltWeit Ludwig Meier e.K.
Contact seller5-star sellerCondition: New
£ 44.17
£ 19.76 shippingShips from Germany to U.S.A.Quantity: 2 available
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -The objective of this study is to formulate and evaluate the sustained release matrix tablet of Tizanidine Hydrochloride by direct compression method. In the present study, Tizanidine is chosen as a model drug which is Muscle relaxa…nt. Because of its short half life (2.5hrs), its water solubility and less bioavailability (40%) it was chosen as a suitable candidate for sustain matrix tablet formulation. It was formulated in to matrix tablet using polymer such as iota-Carrageenan and Polyethylene oxide as releases retardants. All the pre-compression parameters, post-compression parameters were found to be within the standard IP limits. Matrix tablet with Carrageenan and Polyethylene oxide successfully sustained the release of Tizanidine for a period of 12hrs. The concentration of tizanidine was kept constant, MCC-101 and lactose (1:3 ratio) used as filler. The maximum in-vitro release (at 50rpm, temperature 37±0.5°C, and 0.1N HCl, pH 6.8 phosphate buffers) was found to be 97.8% and 98.6% over a period of 12hrs for formulations C4 and P4. The data of in-vitro release from tablets were fitted to different kinetic models to explain the release profile. Formulations C4 and P4 were best 104 pp. Englisch.
Formulation and Evaluation of Sustained release tablets of Tizanidine
Yamsani Vamshi Vishnu|Venkata Raghava Reddy P.|Rayala Venkatakoteswararao
- Softcover
- Print on Demand
Seller: moluna, Greven, Germanymoluna
Contact seller5-star sellerCondition: New
£ 36.91
£ 42.10 shippingShips from Germany to U.S.A.Quantity: Over 20 available
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Vamshi Vishnu YamsaniResearch of interest in the field of TDDS Buccal film, nanoparticles & various drug delivery systems and published 36 international & 4 national journals & visited 2 universities in… U.S.A. Attended various intern.
Language: English
Published by LAP LAMBERT Academic Publishing Feb 2017, 2017
- Softcover
- Print on Demand
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germanybuchversandmimpf2000
Contact seller5-star sellerCondition: New
£ 44.17
£ 51.56 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. This item is printed on demand - Print on Demand Titel. Neuware -The objective of this study is to formulate and evaluate the sustained release matrix tablet of Tizanidine Hydrochloride by direct compression method. In the present study, Tizanidine is chosen as a model drug which is Muscle relaxant.…Because of its short half life (2.5hrs), its water solubility and less bioavailability (40%) it was chosen as a suitable candidate for sustain matrix tablet formulation. It was formulated in to matrix tablet using polymer such as iota-Carrageenan and Polyethylene oxide as releases retardants. All the pre-compression parameters, post-compression parameters were found to be within the standard IP limits. Matrix tablet with Carrageenan and Polyethylene oxide successfully sustained the release of Tizanidine for a period of 12hrs. The concentration of tizanidine was kept constant, MCC-101 and lactose (1:3 ratio) used as filler. The maximum in-vitro release (at 50rpm, temperature 37±0.5°C, and 0.1N HCl, pH 6.8 phosphate buffers) was found to be 97.8% and 98.6% over a period of 12hrs for formulations C4 and P4. The data of in-vitro release from tablets were fitted to different kinetic models to explain the release profile. Formulations C4 and P4 were bestVDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 104 pp. Englisch.
- Softcover
- Print on Demand
Seller: AHA-BUCH GmbH, Einbeck, GermanyAHA-BUCH GmbH
Contact seller5-star sellerCondition: New
£ 44.17
£ 52.30 shippingShips from Germany to U.S.A.Quantity: 1 available
Taschenbuch. Condition: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - The objective of this study is to formulate and evaluate the sustained release matrix tablet of Tizanidine Hydrochloride by direct compression method. In the present study, Tizanidine is chosen as a model drug which is Muscle relaxant. B…ecause of its short half life (2.5hrs), its water solubility and less bioavailability (40%) it was chosen as a suitable candidate for sustain matrix tablet formulation. It was formulated in to matrix tablet using polymer such as iota-Carrageenan and Polyethylene oxide as releases retardants. All the pre-compression parameters, post-compression parameters were found to be within the standard IP limits. Matrix tablet with Carrageenan and Polyethylene oxide successfully sustained the release of Tizanidine for a period of 12hrs. The concentration of tizanidine was kept constant, MCC-101 and lactose (1:3 ratio) used as filler. The maximum in-vitro release (at 50rpm, temperature 37±0.5°C, and 0.1N HCl, pH 6.8 phosphate buffers) was found to be 97.8% and 98.6% over a period of 12hrs for formulations C4 and P4. The data of in-vitro release from tablets were fitted to different kinetic models to explain the release profile. Formulations C4 and P4 were best.
